| Trial ID: | L4893 |
| Source ID: | NCT02673138
|
| Associated Drug: |
Canagliflozin
|
| Title: |
Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02673138/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: canagliflozin|OTHER: basal interruption without canagliflozin
|
| Outcome Measures: |
Primary: Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin, The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor., 20 hours|Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal, 20 hours | Secondary: Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion, 20 hours|Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion, 20 hours
|
| Sponsor/Collaborators: |
Sponsor: Yale University | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-01
|
| Completion Date: |
2017-07
|
| Results First Posted: |
2018-11-29
|
| Last Update Posted: |
2021-10-13
|
| Locations: |
Yale University School of Medicine, New Haven, Connecticut, 06520, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02673138
|
